Rebound covid / tested positive again; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (Rebound covid / tested positive again) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 065F21A, 027B21A and 002B21A) for COVID-19 vaccination.     Concurrent medical conditions included Asthma, Obesity (Obese) and Allergy (Drug was not specified). Concomitant products included LISDEXAMFETAMINE MESILATE (VYVANSE), DUPILUMAB (DUPIXENT), TOPIRAMATE, LAMOTRIGINE, BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT), SALBUTAMOL (VENTOLIN [SALBUTAMOL]), VITAMIN D NOS, VITAMIN B12 NOS, VITAMIN B2 [RIBOFLAVIN], MULTIVITAMINS [VITAMINS NOS], PROBIOTICS NOS, MAGNESIUM and CALCIUM for an unknown indication.   On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 12-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (Rebound covid / tested positive again). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 20-May-2022 to 24-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Rebound covid / tested positive again) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 25-May-2022, SARS-CoV-2 test: negative (Negative) tested negative after paxlovid treatment.. On 26-May-2022, SARS-CoV-2 test: positive (Positive) Started experiencing symptoms again 2 days after Paxlovid, took another home test, tested positive again..         It was reported that the patient tested negative day after finishing paxlovid. Patient started experiencing symptoms again 2 days after that, Patient took another test at home and tested positive again.  The patient was taking other medications/products within 2 weeks of starting COVID-19 treatment. The patient previously received a COVID-19 Vaccine. Device date was reported as 29-May-2022.  Company Comment: This spontaneous case concerns a 34-year-old, female patient with relevant current condition of asthma who experienced the unexpected, non-serious adverse event of special interest of COVID-19 which occurred approximately six months after receiving the third dose of mRNA-1273 vaccine. Primary series of vaccination with mRNA-1273 was completed seven months prior to the current dose. Patient developed COVID-19 on unspecified date and was treated with 5-day course of Nirmatrelvir, Ritonavir (Paxlovid). Clinical presentation of COVID-19 was not specified however it was reported that COVID-19 symptoms recurred 2 days after the completion of anti-viral treatment. She also retested positive for COVID-19 after a negative test. The clinical course, diagnostic investigations, and treatment details after recurrence of positive test were not reported. Current condition of asthma remains a confounder for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a 34-year-old, female patient with relevant current condition of asthma who experienced the unexpected, non-serious adverse event of special interest of COVID-19 which occurred approximately six months after receiving the third dose of mRNA-1273 vaccine. Primary series of vaccination with mRNA-1273 was completed seven months prior to the current dose. Patient developed COVID-19 on unspecified date and was treated with 5-day course of Nirmatrelvir, Ritonavir (Paxlovid). Clinical presentation of COVID-19 was not specified however it was reported that COVID-19 symptoms recurred 2 days after the completion of anti-viral treatment. She also retested positive for COVID-19 after a negative test. The clinical course, diagnostic investigations, and treatment details after recurrence of positive test were not reported. Current condition of asthma remains a confounder for the event. The benefit-risk relationship of mRNA-1273 is not affected by this report.